As­traZeneca's con­cur­rent Imfinzi-chemo-ra­di­a­tion com­bo in lung can­cer miss­es pri­ma­ry end­point in PhI­II tri­al

As­traZeneca’s PD-L1 Imfinzi failed a Phase III tri­al in non-small cell lung can­cer (NSCLC) when in­ves­ti­gat­ed con­cur­rent­ly with chemora­dio­ther­a­py (CRT) as the com­pa­ny worked to ex­pand the drug’s use from se­quen­tial ad­min­is­tra­tion and get im­munother­a­py in­to pa­tients ear­li­er.

In the PA­CIF­IC-2 tri­al, Imfinzi and CRT didn’t hit sta­tis­ti­cal sig­nif­i­cance for the pri­ma­ry end­point, pro­gres­sion-free sur­vival, when test­ed against chemora­dio­ther­a­py alone in pa­tients with un­re­sectable, stage 3 NSCLC.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.